alpha-adrenergic receptor
16 drugs4
approved indications
16
Approved Drugs
13
Companies
6
Indications
0
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (13 companies)
✓ All 16 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (6 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
PH HEALTH 2 drugs
Fresenius Kabi 2 drugs
Viatris 2 drugs
By Therapeutic Area
Other 16 drugs
Drugs by Company PRO
Fresenius Kabi 2 drugs
Viatris 2 drugs
ADAMIS PHARMS CORP 1 drug
IMPAX 1 drug
ARS PHARMS OPERATION 1 drug
Teva 1 drug
SAGENT 1 drug
NEXUS 1 drug
Pfizer 1 drug
+ 3 more companies
By Therapeutic Area
Other 16 drugs
ADRENALIN, SYMJEPI, ADRENACLICK, XYLOCAINE W/ EPINEPHRINE +12 more
Indications Treated
HypotensionSeptic ShockAnaphylaxisAllergic ReactionsAllergic ReactionType I Allergic Reaction
All Drugs Targeting alpha-adrenergic receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| ADRENALIN | PH HEALTH | 2012 | 4 | |
| SYMJEPI | ADAMIS PHARMS CORP | 2017 | 2 | |
| ADRENACLICK | IMPAX | 2003 | 2 | |
| XYLOCAINE W/ EPINEPHRINE | Fresenius Kabi | 1948 | 2 | |
| EPIPEN | Viatris | 1987 | 2 | |
| EPIPEN JR. | Viatris | 1987 | 2 | |
| NEFFY | ARS PHARMS OPERATION | 2024 | 2 | |
| EPINEPHRINE (AUTOINJECTOR) | Teva | 2018 | 2 | |
| NOREPINEPHRINE BITARTRATE | Fresenius Kabi | 2003 | 1 | |
| CORPHEDRA | PH HEALTH | 2017 | 1 | |
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | SAGENT | 2021 | 1 | |
| EMERPHED | NEXUS | 2020 | 1 | |
| LEVOPHED | Pfizer | 1950 | 1 | |
| AKOVAZ | EXELA PHARMA | 2016 | 1 | |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | LONG GROVE PHARMS | 2022 | 1 | |
| ORAVERSE | SEPTODONT HOLDING | 2008 | - |